130 results about "Cathelicidins" patented technology

The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.

Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

The present invention is directed to compounds of Formula I:wherein R1, R2 and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are inhibitors of Cathepsin C.

This invention relates to 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

The invention relates to a variant cathelicidin-BF15 of bungarus fasciatus antibiosis peptide cathelicidin-BF and application thereof. The invention belongs to the field of biomedicine. The variant cathelicidin-BF15 of the bungarus fasciatus antibiosis peptide cathelicidin-BF is a straight chain polypeptide which contains 15 amino acid residues with the molecular weight of 1,939.47Da and an isoelectric point of 12.05. The total sequence of the cathelicidin-BF15 is as follows:valine-lysine-arginine-phenylalanine-lysine-lysine-phenylalanine-phenylalanine-arginine-lysine-leucine-lysine-lysine-serine-valine. The cathelicidin-BF15 which has strong bactericidal action can exterminate a plurality of clinical drug-fast bacteria. In addition, the cathelicidin-BF15 is also characterized by simple structure, convenient synthesis, broad spectrum antibiosis, and the like.

This invention relates to a compound of formula Iand their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

The present invention relates to an agent for increasing BMD characterized by use of a cathepsin K inhibitor as a bone resorption inhibitor in combination with a type of PTH as a bone formation stimulator. This agent for increasing BMD is useful for the treatment of osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcemia, osteometastasis of carcinoma, periodontal disease, bone Paget's disease and other bone metabolic diseases. For example, as the cathepsin K inhibitor, there can be mentioned a compound of formula (W) and a salt thereof, etc.

The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.

The invention relates to a preparation method of a submicron emulsion repairing stock solution composition and a cosmetic composition containing the submicron emulsion repairing stock solution composition. The submicron emulsion repairing stock solution composition is prepared from oligopeptide-3, oligopeptide-1, Indolicidin or an analogue thereof, Cathelicidin-BF, hyaluronic acid, glycerol, minkoil, lecithin, starch sodium octenylsuccinate, fatty alcohol polyoxyethylene ether, hydroxyethyl cellulose, propylene glycol / bis(hydroxymethyl)imidazolidinyl urea / methylparaben / iodopropynyl butylcarbamate and the like. A submicron emulsion repairing stock solution has the effects of keeping moisture and repairing, resisting bacteria and removing acnes. The repairing stock solution composition canbe used for promoting growth and cracking of various cells in epidermal tissues, promoting the growth of collagen, repairing aged collagen elastic fibers and recovering skin activity; especially, thesubmicron emulsion repairing stock solution composition has remarkable repairing effects on various epidermal wounds including acne marks, phototherapy, scalds and the like.

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

The invention discloses skin repair peptide cathelicidin-NV of nanorana pleskei as well as a gene and application thereof, and belongs to the field of biomedicines. The skin repair peptide cathelicidin-NV is a ring type polypeptide encoded by a defense peptide gene of nanorana ventripunctata which is a special species belongs to the Chinese amphibian; the molecular weight is 2845.9 Dalton, and theisoelectric point is 9.90; the amino acid sequence of the skin repair peptide cathelicidin-NV is shown in SEQ ID NO: 1. The gene GenBank accession No.(MH010580) for encoding a skin repair peptide cathelicidin-NV precursor comprises 652 nucleotide sequences, and each nucleotide sequence is shown in SEQ ID NO: 2; nucleotides at sites from 367 to 438 are encoding genes of the skin repair peptide cathelicidin-NV of the nanorana pleskei. The invention further discloses the application of the skin repair peptide cathelicidin-NV of the nanorana pleskei in preparation of a treatment drug for promoting skin wound repairing. The skin repair peptide cathelicidin-NV has the beneficial effect that the skin repair peptide cathelicidin-NV has a relatively strong effect of promoting wound healing of a skin wound, and the wound healing promoting effect of the skin repair peptide cathelicidin-NV is similar to that of an epidermal growth factor (EGF).

Antimicrobial peptides and methods for their use are provided. The peptides are optimized, truncated versions of chicken cathelicidins (“fowlicidins”).